Sangamo Therapeutics, Inc (SGMOQ) Stock Price & Analysis
Sangamo Therapeutics, Inc (SGMOQ) rose 0.00% to USD 0.07 as of July 25, 2026 at 07:28 UTC, according to Nexqual real-time market data.
SGMOQ last closed at USD 0.07; the session ranged USD 0.06–0.08 on volume of 2,060,860 shares. Market capitalization is —, with a 52-week range of USD 0.03–0.77 (OID). Source: Nexqual, July 25, 2026 at 07:28 UTC.
Key Statistics (as of July 25, 2026 at 07:28 UTC)
| Price | USD 0.07 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.07 |
| Open | USD 0.08 |
| Day Range | USD 0.06 – 0.08 |
| 52-Week Range | USD 0.03 – 0.77 |
| Volume | 2,060,860 shares |
| Market Cap | — |
| Exchange | OID |
Technical Analysis (SGMOQ)
Nexqual's technical model rates SGMOQ "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 07:28 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.87 (neutral) |
| vs SMA50 | Below (USD 0.13) |
| MACD | -0.02 (negative) |
Analyst Ratings (SGMOQ)
Wall Street analysts rate SGMOQ "None", per Nexqual as of July 25, 2026 at 07:28 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (SGMOQ)
| Next Earnings Date | 2026-08-06 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.08 vs est -0.07 ▼ miss |
| 2025-12-31 | USD -0.07 vs est -0.05 ▼ miss |
| 2025-09-30 | USD -0.11 vs est -0.1 ▼ miss |
| 2025-06-30 | USD -0.08 vs est -0.13 ▲ beat |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financials & Fundamentals (SGMOQ)
| Total Revenue | $34.56M |
|---|---|
| Revenue Growth (YoY) | -77.60% |
| Gross Margin | -227.67% |
| Operating Margin | -2215.39% |
| Profit Margin | +0.00% |
| Current Ratio | 0.7 |
| Total Cash | $27.59M |
| Total Debt | $19.33M |
| Free Cash Flow | $-48.58M |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financial Health Score (SGMOQ)
Nexqual rates Sangamo Therapeutics, Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:28 UTC.
| Growth | Critical — Revenue -32% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $28M cash vs $19M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$49M, burning cash |
| Efficiency | Mixed — No data |
Ownership (SGMOQ)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +24.19% |
| Float | 370.04M |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Leadership (SGMOQ)
Sangamo Therapeutics, Inc is led by Alexander D. Macrae Ch.B, M.B., MRCP (age 62), CEO, President & Director, per Nexqual as of July 25, 2026 at 07:28 UTC.
| CEO, President & Director | Alexander D. Macrae Ch.B, M.B., MRCP (age 62) |
|---|---|
| Interim CFO and Principal Financial & Accounting Officer | Nikunj Jain (age 45) |
Major Backers & Investors (SGMOQ)
Notable institutional backers of Sangamo Therapeutics, Inc include Armistice Capital, LLC, Two Sigma Investments, LP, Balyasny Asset Management LP, according to Nexqual as of July 25, 2026 at 07:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.74% |
| Two Sigma Investments, LP | 1.51% |
| Balyasny Asset Management LP | 1.27% |
| Renaissance Technologies | 0.92% |
| UBS Group AG | 0.62% |
| Charles Schwab Investment Management, Inc. | 0.57% |
| Charles Schwab | 0.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.67% |
| BlackRock | 1.1% |
| Geode Capital | 1.1% |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
From Sangamo Therapeutics, Inc's Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States.
- Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. ALS and Frontotemporal Lobar Degeneration; Takeda Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc.
- On June 23, 2026, Sangamo Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EDIT | Editas Medicine, Inc. | USD 2.6 | ▼ 6.47% |
| NTLA | Intellia Therapeutics, Inc. | USD 10.73 | ▼ 3.59% |
| NKTR | Nektar Therapeutics | USD 70.73 | ▲ 2.03% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| QURE | uniQure N.V. | USD 38.97 | ▼ 3.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:28 UTC. This page is informational and not investment advice.